Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 9:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 50 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Philip Philip Clear all
Completed Phase 2 Interventional Results available

Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers

NCT01806779
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Chantix, Zyban, Nicotine patches
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Charlotte, North Carolina • Durham, North Carolina • Raleigh, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 5, 2026, 9:39 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants

NCT01560507
View directory record Official record
Conditions
Cigarette Smoking, Nicotine Dependence
Interventions
varenicline (Chantix), bupropion (Zyban), nicotine patches
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 5, 2026, 9:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2

NCT02649556
View directory record Official record
Conditions
Smoking
Interventions
THS 2.2, CC
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
30 Years and older
Enrollment
672 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
19
States / cities
Tempe, Arizona • Clearwater, Florida • Daytona Beach, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 5, 2026, 9:39 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype

NCT00894166
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine Patches, Nicotine patches, then bupropion & nicotine patches (Pre-Quit), Nicotine patches, then varenicline (Pre-Quit), Nicotine patches, then nicotine patches (Pre-Quit), Nicotine patches, then bupropion & nicotine patches (Post-Quit), Nicotine patches, then varenicline (Post-Quit), Nicotine patches, then nicotine patches (Post-Quit)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Charlotte, Durham, Raleigh, Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 5, 2026, 9:39 AM EDT
Not yet recruiting Not applicable Interventional

EarFlo: A Non-Invasive Treatment for Otitis Media With Effusion & Eustachian Tube Dysfunction in Adults

NCT07777302
View directory record Official record
Conditions
Otitis Media With Effusion (OME), Eustachian Tube Dysfunction, Otitis Media With Effusion
Interventions
EarFlo Device
Device
Lead sponsor
Philip Perez
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 5, 2026, 9:39 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

NCT05051436
View directory record Official record
Conditions
Pre-diabetes, Obesity
Interventions
Mirabegron 50 MG, Tadalafil 10 MG, Placebo
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 5, 2026, 9:39 AM EDT
Terminated No phase listed Observational

EPR Tumor Oximetry With CE India Ink

NCT03321903
View directory record Official record
Conditions
Neoplasms, Malignant, Breast Neoplasm, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasm, Head and Neck Neoplasms
Interventions
Carlo Erba Ink Injection, EPR Oximetry Measurement
Device · Other
Lead sponsor
Philip Schaner
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Oct 5, 2026, 9:39 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

RELIANCE: Moringa in Lactation and Early Childhood

NCT07605091
View directory record Official record
Conditions
Breast Feeding, Lactation
Interventions
Moringa Leaf Powder, Carrier
Dietary Supplement · Other
Lead sponsor
Philip Kern
Other
Eligibility
7 Days to 99 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 5, 2026, 9:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mechanisms Underlying Metabolic Syndrome in Obesity

NCT00579813
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance, Prediabetes
Interventions
Pioglitazone
Drug
Lead sponsor
Philip Kern
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
2
States / cities
Little Rock, Arkansas • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 5, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

Meclizine as a Potential Smoking Cessation Treatment

NCT01443858
View directory record Official record
Conditions
Smoking Cessation
Interventions
Meclizine, Nicotine Patch, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Charlotte, North Carolina • Durham, North Carolina • Raleigh, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 5, 2026, 9:39 AM EDT
Completed No phase listed Observational

Alveolar Macrophage Proteomics in HIV-associated Emphysema

NCT00823927
View directory record Official record
Conditions
HIV, Emphysema, HIV Infections
Interventions
Not listed
Lead sponsor
Philip Diaz
Other
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 5, 2026, 9:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

User Acceptability of a Nicotine Lactate Delivery System (P3L)

NCT02643693
View directory record Official record
Conditions
Smoking
Interventions
P3L, VUSE, CC
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
19 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 5, 2026, 9:39 AM EDT
Recruiting No phase listed Observational

The Effects of the CF Carrier State on the Kidneys and Pancreas

NCT05474417
View directory record Official record
Conditions
Carrier State, Pancreatic Disease, Kidney Diseases
Interventions
Not listed
Lead sponsor
Philip Polgreen
Other
Eligibility
18 Years to 100 Years
Enrollment
1,250 participants
Timeline
2021 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 5, 2026, 9:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes

NCT05383508
View directory record Official record
Conditions
Nicotine Vaping, Nicotine, Vaping
Interventions
CA35, CM35, Cig
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
24 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 5, 2026, 9:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of P4M3 Variants

NCT03379740
View directory record Official record
Conditions
Vaping, Nicotine Absorption
Interventions
E-cigarette, P4M3-1.7%, P4M3-1.7%LA, P4M3-3%LA, P4M3-4%LA
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
21 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 5, 2026, 9:39 AM EDT
Recruiting Phase 1 Interventional

Treatment Targets in Spanish and English Bilingual Speech Intervention

NCT06416306
View directory record Official record
Conditions
Speech Sound Disorder
Interventions
Speech Intervention
Behavioral
Lead sponsor
Philip Combiths
Other
Eligibility
3 Years to 8 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 5, 2026, 9:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting

NCT01989156
View directory record Official record
Conditions
Smoking
Interventions
THS 2.2 Menthol (mTHS 2.2), Menthol Conventional Cigarette (mCC), Smoking Abstinence (SA)
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
22 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 5, 2026, 9:39 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Mechanisms for Activation of Beige Adipose Tissue in Humans

NCT04666636
View directory record Official record
Conditions
PreDiabetes
Interventions
Placebo, Mirabegron, Mirabegron 50 MG, Mirabegron 100 mg
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 5, 2026, 9:39 AM EDT
Withdrawn Not applicable Interventional

Randomized Trial of Supercharged End-to-Side Anterior Interosseous Nerve Transfer for Severe Cubital Tunnel Syndrome

NCT04647058
View directory record Official record
Conditions
Cubital Tunnel Syndrome, Ulnar Nerve Compression, Ulnar Nerve Palsy, Ulnar Nerve Entrapment, Ulnar Nerve Entrapment at Elbow, Ulnar Nerve Entrapment Syndrome, Ulnar Neuropathies, Ulnar Claw
Interventions
Cubital tunnel release, Supercharged end-to-side (SETS) nerve transfer
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 5, 2026, 9:39 AM EDT
Completed Phase 4 Interventional Results available

Statin Therapy for Ischemic and Nonischemic Cardiomyopathy

NCT00701220
View directory record Official record
Conditions
Cardiovascular Disease, Cardiomyopathy, Heart Disease, Myocardial Disease, Myocardial Ischemia
Interventions
Atorvastatin Calcium
Drug
Lead sponsor
Philip Binkley
Other
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 5, 2026, 9:39 AM EDT
Withdrawn Phase 2 Interventional

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

NCT03549689
View directory record Official record
Conditions
HIV/AIDS, HIV-1-infection, Osteopenia
Interventions
Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC), Current tenofovir alafenamide (TAF)-containing ART regimen
Drug
Lead sponsor
Philip Grant
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Oct 5, 2026, 9:39 AM EDT
Completed Phase 3 Interventional Results available

Concurrent Bupropion / Varenicline for Smoking Cessation

NCT01303861
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Varenicline, Bupropion, Nicotine patches, Nicotine Inhaler
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Charlotte, North Carolina • Durham, North Carolina • Raleigh, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 5, 2026, 9:39 AM EDT
Completed Early Phase 1 Interventional

Brown Fat Activation Study

NCT02919176
View directory record Official record
Conditions
Obese, Metabolic Syndrome
Interventions
Mirabegron, Pioglitazone, Mirabegron and Pioglitazone
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 5, 2026, 9:39 AM EDT
Completed No phase listed Observational

A Registry of COPD Patients to be Used for Future Studies

NCT00814203
View directory record Official record
Conditions
Chronic Obstructive Lung Disease
Interventions
Not listed
Lead sponsor
Philip Diaz
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 5, 2026, 9:39 AM EDT